MRK—PDUFA for Keytruda-monotherapy sBLA in second-line HCC is 11/9/18 (with priority review): https://www.businesswire.com/news/home/20180711005195/en/FDA-Grants-Priority-Review-Merck%E2%80%99s-Supplemental-Biologics